Shots:
- Varian has reported the European CE Mark approval of Embozene microspheres for genicular artery embolisation (GAE) to treat knee osteoarthritis
- Additionally, a Varian-sponsored GENESIS II trial, assessing GAE vs sham treatment for knee osteoarthritis, has completed patient enrollment in the UK
- GAE aims to reduce knee pain by advancing a small catheter into the genicular arteries & delivering Embozene microspheres to limit blood flow to inflamed areas, ensuring pain relief
Ref: Business wire| Image: Varian | Press Release
Related News:- ONWARD Medical’s ARC-EX System Receives the European CE Mark Approval for Spinal Cord Stimulation
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
